Taysha stops de­vel­op­ing a gene ther­a­py amid de­bate over FDA’s stance on ul­tra-rare tri­als

Taysha Gene Ther­a­pies dis­con­tin­ued de­vel­op­ment of a neu­rode­gen­er­a­tive ther­a­py af­ter the FDA again in­sist­ed on a po­ten­tial­ly im­pos­si­ble study, the com­pa­ny said Tues­day.

It’s yet …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER